Rare eye diseases are the leading cause of untreatable blindness in Europe and affect people of all ages. The RESTORE VISION ...

(NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators.

One such pair that have heaps of glowing reviews are the Adalae High-Waist Wide-Leg Jeans from New Look. Retailing at £34.99 per pair, these jeans have been described by the retailer as "a ...

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin. One day, researchers want to use switches of this ...

Philip Cheung for The New York Times Supported by By Moises Velasquez ... the many tragedies of the opioid epidemic is that a proven treatment for opioid addiction, a drug called buprenorphine ...

The trial found that mastic was effective in controlling the symptoms of 80pc of individuals with duodenal ulcers. Just two weeks of mastic treatment led to complete ulcer healing in 70pc of ...

Philip Cheung for The New York Times Supported by By Moises Velasquez ... But recently he had developed an abscess at an injection site on his leg. Now he was in Highland Hospital, in Oakland ...

In July last year, the company published Phase II trial data indicating that EscharEx outperformed other non-surgical standard-of-care treatments for VLUs. "MediWound commences Phase III trial for ...

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, for treating venous leg ulcers (VLUs ... either the therapy or a placebo.

Here Dr. Usmani discusses the current outlook for the disease and his vision for developing new treatment approaches at MSK that will improve multiple myeloma prognosis (outcome). This includes very ...

MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers. The ...